{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:36Z","timestamp":1792078956846,"version":"4.4.0"},"reference-count":20,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Hypertrophic cardiomyopathy (HCM) is associated with an elevated risk of ventricular arrhythmias and sudden cardiac death (SCD) despite contemporary therapy. Cardiac myosin inhibitors directly target sarcomeric hypercontractility and have demonstrated consistent symptomatic, hemodynamic, and structural benefits in randomized controlled trials (RCTs). However, their effects on malignant ventricular arrhythmias and SCD remain uncertain. This meta-analysis aimed to evaluate the incidence of ventricular arrhythmias and SCD with cardiac myosin inhibitor therapy in HCM. Methods: We conducted a meta-analysis of RCTs evaluating mavacamten or aficamten in patients with HCM. PubMed was systematically searched through September 2025. Eligible trials randomized myosin inhibitors versus control and reported ventricular tachycardia (VT), ventricular fibrillation (VF), or SCD. Results: Seven RCTs including 1519 patients (779 myosin inhibitor; 740 control) were analyzed. Eight composite VT\/VF\/SCD events (1.03%) occurred in the treatment group compared with twelve (1.62%) in controls. Time-standardized incidence rates were 1.48 versus 2.36 per 100 patient-years, respectively. The pooled RR was 0.69 (95% CI 0.27\u20131.74; I2 = 0%), indicating no statistically significant difference. Sensitivity analyses yielded concordant results despite low event counts. Conclusions: No statistically significant increase in ventricular arrhythmia or SCD risk was observed. However, limited events and short follow-up preclude firm conclusions regarding the arrhythmic safety of myosin inhibitors.<\/jats:p>","DOI":"10.3390\/jpm16030159","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:12:25Z","timestamp":1773400345000},"page":"159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of Ventricular Arrhythmias and Sudden Cardiac Death with Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-1919","authenticated-orcid":false,"given":"Josip","family":"Katic","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-2968","authenticated-orcid":false,"given":"Tomislav","family":"Bulum","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-8146","authenticated-orcid":false,"given":"Josip An\u0111elo","family":"Borovac","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital of Split, 21000 Split, Croatia"},{"name":"Department of Health Studies, University of Split, 21000 Split, Croatia"},{"name":"Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Meder, B., Coats, C.J., Leinwand, L.A., Pieroni, M., Garcia-Pavia, P., Desai, M.Y., and Sedaghat-Hamedani, F. (2026). EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy. Eur. J. Heart Fail., Epub ahead of printing.","DOI":"10.1093\/ejhf\/xuaf008"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.amjcard.2023.10.073","article-title":"Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023","volume":"212S","author":"Maron","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mann, C., Tosun, R., Masood, S., Dachs, T.M., Duca, F., Binder-Rodriguez, C., Hengstenberg, C., Gwechenberger, M., Zelniker, T.A., and Dalos, D. (2026). Sex-Specific Differences in Patients with Hypertrophic Cardiomyopathy: A Cohort Study from Vienna. J. Pers. Med., 16.","DOI":"10.3390\/jpm16010056"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.jvca.2025.02.009","article-title":"Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors","volume":"39","author":"Pagel","year":"2025","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","article-title":"The development methods of official GRADE articles and requirements for claiming the use of GRADE\u2014A statement by the GRADE guidance group","volume":"159","author":"Brennan","year":"2023","journal-title":"J. Clin. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 Study of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy","volume":"393","author":"Maron","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin Inhibition in Patients with Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s44348-025-00052-7","article-title":"Cardiac myosin inhibitors in hypertrophic cardiomyopathy","volume":"33","author":"Lim","year":"2025","journal-title":"J. Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"44503","DOI":"10.31083\/RCM44503","article-title":"A New Era in the Management of Hypertrophic Cardiomyopathy","volume":"26","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Teresi, L., Trimarchi, G., Licordari, R., Restelli, D., Taverna, G., Liotta, P., Micari, A., Smecca, I., Dendramis, G., and Turturiello, D. (2025). Hypertrophic Cardiomyopathy Phenocopies: Classification, Key Features, and Differential Diagnosis. Biomedicines, 13.","DOI":"10.20944\/preprints202510.2086.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","article-title":"Practical guide to the meta-analysis of rare events","volume":"21","author":"Efthimiou","year":"2018","journal-title":"Evid. Based Ment. Health"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:00:29Z","timestamp":1773651629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/3\/159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jpm16030159"],"URL":"https:\/\/doi.org\/10.3390\/jpm16030159","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}